Nagorsen D - Search Results

1

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C. Nagorsen D, et al. Cancer Res. 2000 Sep 1;60(17):4850-4. Cancer Res. 2000. PMID: 10987297

2

Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.

Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D. Scheibenbogen C, et al. Among authors: nagorsen d. Int J Cancer. 2002 Mar 20;98(3):409-14. doi: 10.1002/ijc.10205. Int J Cancer. 2002. PMID: 11920592

3

Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.

Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U. Scheibenbogen C, et al. Among authors: nagorsen d. Int J Cancer. 2002 May 20;99(3):403-8. doi: 10.1002/ijc.10328. Int J Cancer. 2002. PMID: 11992409

4

Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.

Nagorsen D, Scheibenbogen C, Schaller G, Leigh B, Schmittel A, Letsch A, Thiel E, Keilholz U. Nagorsen D, et al. Int J Cancer. 2003 Jun 10;105(2):221-5. doi: 10.1002/ijc.11052. Int J Cancer. 2003. PMID: 12673683

5

Natural T cell immunity against cancer.

Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Nagorsen D, et al. Clin Cancer Res. 2003 Oct 1;9(12):4296-303. Clin Cancer Res. 2003. PMID: 14555498 Review.

6

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.

Letsch A, Keilholz U, Fluck M, Nagorsen D, Asemissen AM, Schmittel A, Thiel E, Scheibenbogen C. Letsch A, et al. Among authors: nagorsen d. Int J Cancer. 2005 May 10;114(6):936-41. doi: 10.1002/ijc.20819. Int J Cancer. 2005. PMID: 15645483 Clinical Trial.

7

Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.

Nagorsen D, Thiel E. Nagorsen D, et al. Clin Cancer Res. 2006 May 15;12(10):3064-9. doi: 10.1158/1078-0432.CCR-05-2788. Clin Cancer Res. 2006. PMID: 16707603

8

High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma.

Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E, Scheibenbogen C. Letsch A, et al. Among authors: nagorsen d. Int J Cancer. 2000 Sep 1;87(5):659-64. Int J Cancer. 2000. PMID: 10925359

9

Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells.

Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Schmittel A, Thiel E, Scheibenbogen C. Asemissen AM, et al. Among authors: nagorsen d. J Immunol Methods. 2001 May 1;251(1-2):101-8. doi: 10.1016/s0022-1759(01)00312-x. J Immunol Methods. 2001. PMID: 11292486

10

Immunological monitoring of cancer vaccine therapy.

Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U. Nagorsen D, et al. Expert Opin Biol Ther. 2004 Oct;4(10):1677-84. doi: 10.1517/14712598.4.10.1677. Expert Opin Biol Ther. 2004. PMID: 15461579 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters